Mechanistic Study on the Regulation of Malignant Biological Activity of JAG1 Pathway in Hepatocellular Carcinoma Cells through miR-338-3p by Circ_0007841
GONG Yilin, ZHENG Yunzhou, ZHAO Yanwei, et al
NO.980 Hospital,PLA Joint Logistic Support Force, Hebei Shijiazhuang 050082, China
Abstract:Objective: To explore the regulatory mechanism underlying the malignant biological activity of hepatocellular carcinoma (HCC). Methods: Human-derived normal hepatic epithelial cells THLE-3 and HCC cell lines,including BEL-7405,SNU-387,MHCC-97H,HCCLM3,and Huh7,were used.Huh7 cells were transfected with si-0007841/NC or miR-338-3p inhibitor/NC.Expression levels of circ_0007841,miR-338-3p,and JAG1 were analyzed using qRT-PCR.Proliferation viability,migration,and invasion ability were assessed using CCK-8 and transwell assays.Predictions of the targeting relationships between circ_0007841 and miR-338-3p,as well as miR-338-3p and JAG1,were performed using Circular RNA Interactome and miRWalk datasets.Dual luciferase reporter assays confirmed the target binding. Results: Circ_0007841 was found to be highly expressed in HCC.Inhibiting circ_0007841 expression led to a decrease in proliferation viability and a reduction in migration and invasion abilities of HCC.Further inhibition of miR-338-3p expression partially reversed the inhibitory effects on malignant behavior by low expression of circ_0007841.In HCC,circ_0007841 could target and inhibit the expression of miR-338-3p,while miR-338-3p could target and inhibit the expression of JAG1. Conclusion: High expression of circ_0007841 in hepatocellular carcinoma enhances JAG1 transcription by competitively binding with miR-338-3p,ultimately promoting malignant biological activities in HCC cells.
龚一林, 郑运周, 赵艳微, 张洪雨, 黄涛. Circ_0007841通过miR-338-3p靶向JAG1促进肝癌细胞恶性生物学活性的机制研究[J]. 河北医学, 2023, 29(11): 1795-1800.
GONG Yilin, ZHENG Yunzhou, ZHAO Yanwei, et al. Mechanistic Study on the Regulation of Malignant Biological Activity of JAG1 Pathway in Hepatocellular Carcinoma Cells through miR-338-3p by Circ_0007841. HeBei Med, 2023, 29(11): 1795-1800.
[1] Sung H,Ferlay J,Siegel R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer Clin,2021,71(3):209-249. [2] Xu M,Yang L,Lin Y,et al.Emerging nanobiotechnology for precise theranostics of hepatocellular carcinoma[J].Nanobiotechnology,2022,20(1):427. [3] Ding J,Wen Z.Survival improvement and prognosis for hepatocellular carcinoma:analysis of the SEER database[J].BMC Cancer,2021,21(1):1157. [4] Chen L,Shan G.CircRNA in cancer:Fundamental mechanism and clinical potential[J].Cancer Lett,2021,505:49-57. [5] Zhang Q,Wang W,Zhou Q,et al.Roles of circRNAs in the tumour microenvironment[J].Mol Cancer,2020,19(1):14. [6] Wang J,Wen Y,Xu J,et al.CircRIMKLB promotes myoblast proliferation and inhibits differentiation by sponging miR-29c to release KCNJ12[J].Epigenetics,2022,17(12):1686-700. [7] Li J,Xu Q,Huang Z J,et al.CircRNAs:a new target for the diagnosis and treatment of digestive system neoplasms[J].Cell Death Dis,2021,12(2):205. [8] Long F,Li Z,Wei Z,et al.Circular RNA circ_0007841 participates in progression of nonsmall cell lung cancer via miR-199a-5p/SphK2 axis[J].Anticancer Drugs,2022,33(10):1035-46. [9] Gao Y,Huang Y.Circ_0007841 knockdown confers cisplatin sensitivity to ovarian cancer cells by down-regulation of NFIB expression in a miR-532-5p-dependent manner[J].Chemother,2023,35(2):117-30. [10] Wang Y,Lin Q,Song C,et al.Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis[J].Cell Cycle,2020,19(23):3289-302. [11] Hao X,Zhang Y,Shi X,et al.CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ[J].Exp Clin Cancer Res,2022,41(1):281. [12] Li Y,Wu A,Chen L,et al.Hsa_circ_0000098 is a novel therapeutic target that promotes hepatocellular carcinoma development and resistance to doxorubicin[J].Exp Clin Cancer Res,2022,41(1):267.